Table S1 from Analysis of Mucosal Melanoma Whole-Genome Landscapes Reveals Clinically Relevant Genomic Aberrations

Rong Zhou,Chaoji Shi,Wenjie Tao,Jiang Li,Jing Wu,Yong Han,Guizhu Yang,Ziyue Gu,Shengming Xu,Yujue Wang,Lizhen Wang,Yanan Wang,Guoyu Zhou,Chenping Zhang,Zhiyuan Zhang,Shuyang Sun

DOI: https://doi.org/10.1158/1078-0432.22475283.v1

2023-01-01

Abstract:Whole Genome Sequencing metrics and clinical data of MMs.

What problem does this paper attempt to address?

Table S3 from Analysis of Mucosal Melanoma Whole-Genome Landscapes Reveals Clinically Relevant Genomic Aberrations

Rong Zhou,Chaoji Shi,Wenjie Tao,Jiang Li,Jing Wu,Yong Han,Guizhu Yang,Ziyue Gu,Shengming Xu,Yujue Wang,Lizhen Wang,Yanan Wang,Guoyu Zhou,Chenping Zhang,Zhiyuan Zhang,Shuyang Sun

DOI: https://doi.org/10.1158/1078-0432.22475277.v1

2023-01-01

Abstract:Pathway analysis in MM and comparison between MM and CM.
Table S2 from Analysis of Mucosal Melanoma Whole-Genome Landscapes Reveals Clinically Relevant Genomic Aberrations

Rong Zhou,Chaoji Shi,Wenjie Tao,Jiang Li,Jing Wu,Yuexin Han,Guizhu Yang,Ziyue Gu,Shengming Xu,Yujue Wang,Lizhen Wang,Yanan Wang,Guoyu Zhou,Chenping Zhang,Zhiyuan Zhang,Shasha Sun

DOI: https://doi.org/10.1158/1078-0432.22475280.v1

2023-01-01

Abstract:Significantly mutated genes,promoters and UTRs of MMs.
Table S6 from Analysis of Mucosal Melanoma Whole-Genome Landscapes Reveals Clinically Relevant Genomic Aberrations

Rong Zhou,Chaoji Shi,Wenjie Tao,Jiang Li,Jing Wu,Yong Han,Guizhu Yang,Ziyue Gu,Shengming Xu,Yujue Wang,Lizhen Wang,Yanan Wang,Guoyu Zhou,Chenping Zhang,Zhiyuan Zhang,Shuyang Sun

DOI: https://doi.org/10.1158/1078-0432.22475268.v1

2023-01-01

Abstract:Supplementary figures and figure legends. (Figure S1) Deregulation of genes within key affected signaling pathways in MM. (Figure S2) Validation of the somatic SNV/InDels found in POM121. (Figure S3) Copy number changes in MM. (Figure S4) Distribution of SVs and genetic events including breakage-fusion-bridges [BFBs] and chromothripsis across chromosomes among all samples. (Figure S5) Validation of SV occurring between chromosome 5 and 12 in MM023 and MM065. (Figure S6) Fine structure of BFBs and chromothripsis found in MM. (Figure S7) Comparison of lesions found in mucosal melanoma. (Figure S8) Validation of the copy number alteration of CDK4 and TERT in representative samples. (Figure S9) FISH confirming amplification and co-localization of CDK4 [12q14] and TERT [5p15]. (Figure S10) Molecular characterization of the MM PDX models and the effects of palbociclib on Rb phosphorylation in treatment-responsive PDX models. (Figure S11) Significant mutated non-coding region genes in MMs. (Figure S12) Mutation signatures found in MM.
Analysis of Mucosal Melanoma Whole-Genome Landscapes Reveals Clinically Relevant Genomic Aberrations

Rong Zhou,Chaoji Shi,Wenjie Tao,Jiang Li,Jing Wu,Yong Han,Guizhu Yang,Ziyue Gu,Shengming Xu,Yujue Wang,Lizhen Wang,Yanan Wang,Guoyu Zhou,Chenping Zhang,Zhiyuan Zhang,Shuyang Sun

DOI: https://doi.org/10.1158/1078-0432.ccr-18-3442

IF: 13.801

2019-01-01

Clinical Cancer Research

Abstract:AbstractPurpose: Unlike advances in the genomics-driven precision treatment of cutaneous melanomas, the current poor understanding of the molecular basis of mucosal melanomas (MM) has hindered such progress for MM patients. Thus, we sought to characterize the genomic landscape of MM to identify genomic alterations with prognostic and/or therapeutic implications. Experimental Design: Whole-genome sequencing (WGS) was performed on 65 MM samples, including 63 paired tumor blood samples and 2 matched lymph node metastases, with a further droplet digital PCR–based validation study of an independent MM cohort (n = 80). Guided by these molecular insights, the FDA-approved CDK4/6 inhibitor palbociclib was tested in an MM patient-derived xenograft (PDX) trial. Results: Besides the identification of well-recognized driver mutations of BRAF (3.1%), RAS family (6.2%), NF1 (7.8%), and KIT (23.1%) in MMs, our study also found that (i) mutations and amplifications in the transmembrane nucleoporin gene POM121 (30.8%) defined a patient subgroup with higher tumor proliferation rates; (ii) enrichment of structural variations between chromosomes 5 and 12 defined a patient subgroup with significantly worse clinical outcomes; (iii) over 50% of the MM patients harbored recurrent focal amplification of several oncogenes (CDK4, MDM2, and AGAP2) at 12q13-15, and this co-occurred significantly with amplification of TERT at 5p15, which was verified in the validation cohort; (iv) the PDX trial demonstrated robust antitumor effects of palbociclib in MMs harboring CDK4 amplification. Conclusions: Our largest-to-date cohort WGS analysis of MMs defines the genomic landscape of this deadly cancer at unprecedented resolution and identifies genomic aberrations that could facilitate the delivery of precision cancer treatments. See related commentary by Shoushtari, p. 3473
Single-Cell Characterization of the Immune Microenvironment of Melanoma Brain and Leptomeningeal Metastases.

Inna Smalley,Zhihua Chen,Manali Phadke,Jiannong Li,Xiaoqing Yu,Clayton Wyatt,Brittany Evernden,Jane L. Messina,Amod Sarnaik,Vernon K. Sondak,Chaomei Zhang,Vincent Law,Nam Tran,Arnold Etame,Robert J. B. Macaulay,Zeynep Eroglu,Peter A. Forsyth,Paulo C. Rodriguez,Y. Ann Chen,Keiran S. M. Smalley

DOI: https://doi.org/10.1158/1078-0432.ccr-21-1694

2021-01-01

Neuro-Oncology Advances

Abstract:Abstract Purpose: Melanoma brain metastases (MBM) and leptomeningeal melanoma metastases (LMM) are two different manifestations of melanoma CNS metastasis. Here, we used single-cell RNA sequencing (scRNA-seq) to define the immune landscape of MBM, LMM, and melanoma skin metastases. Experimental Design: scRNA-seq was undertaken on 43 patient specimens, including 8 skin metastases, 14 MBM, and 19 serial LMM specimens. Detailed cell type curation was performed, the immune landscapes were mapped, and key results were validated by IHC and flow cytometry. Association analyses were undertaken to identify immune cell subsets correlated with overall survival. Results: The LMM microenvironment was characterized by an immune-suppressed T-cell landscape distinct from that of brain and skin metastases. An LMM patient with long-term survival demonstrated an immune repertoire distinct from that of poor survivors and more similar to normal cerebrospinal fluid (CSF). Upon response to PD-1 therapy, this extreme responder showed increased levels of T cells and dendritic cells in their CSF, whereas poor survivors showed little improvement in their T-cell responses. In MBM patients, therapy led to increased immune infiltrate, with similar T-cell transcriptional diversity noted between skin metastases and MBM. A correlation analysis across the entire immune landscape identified the presence of a rare population of dendritic cells (DC3) that was associated with increased overall survival and positively regulated the immune environment through modulation of activated T cells and MHC expression. Conclusions: Our study provides the first atlas of two distinct sites of melanoma CNS metastases and defines the immune cell landscape that underlies the biology of this devastating disease.
Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets.

Felicity Newell,Yan Kong,James S Wilmott,Peter A Johansson,Peter M Ferguson,Chuanliang Cui,Zhongwu Li,Stephen H Kazakoff,Hazel Burke,Tristan J Dodds,Ann-Marie Patch,Katia Nones,Varsha Tembe,Ping Shang,Louise van der Weyden,Kim Wong,Oliver Holmes,Serigne Lo,Conrad Leonard,Scott Wood,Qinying Xu,Robert V Rawson,Pamela Mukhopadhyay,Reinhard Dummer,Mitchell P Levesque,Göran Jönsson,Xuan Wang,Iwei Yeh,Hong Wu,Nancy Joseph,Boris C Bastian,Georgina V Long,Andrew J Spillane,Kerwin F Shannon,John F Thompson,Robyn P M Saw,David J Adams,Lu Si,John V Pearson,Nicholas K Hayward,Nicola Waddell,Graham J Mann,Jun Guo,Richard A Scolyer

DOI: https://doi.org/10.1038/s41467-019-11107-x

IF: 16.6

2019-01-01

Nature Communications

Abstract:Knowledge of key drivers and therapeutic targets in mucosal melanoma is limited due to the paucity of comprehensive mutation data on this rare tumor type. To better understand the genomic landscape of mucosal melanoma, here we describe whole genome sequencing analysis of 67 tumors and validation of driver gene mutations by exome sequencing of 45 tumors. Tumors have a low point mutation burden and high numbers of structural variants, including recurrent structural rearrangements targeting TERT, CDK4 and MDM2. Significantly mutated genes are NRAS, BRAF, NF1, KIT, SF3B1, TP53, SPRED1, ATRX, HLA-A and CHD8. SF3B1 mutations occur more commonly in female genital and anorectal melanomas and CTNNB1 mutations implicate a role for WNT signaling defects in the genesis of some mucosal melanomas. TERT aberrations and ATRX mutations are associated with alterations in telomere length. Mutation profiles of the majority of mucosal melanomas suggest potential susceptibility to CDK4/6 and/or MEK inhibitors.
Table S1 from Comparative Epigenetic Profiling Reveals Distinct Features of Mucosal Melanomas Associated with Immune Cell Infiltration and Their Clinical Implications

Jie Dai,Jia Jia,Fanshuang Zhang,Kaihua Liu,Yanfeng Xi,Pei Yuan,Lili Mao,Xue Bai,Xiaoting Wei,Bingning Wang,Jiangtao Li,Yang Xu,Ting Liu,Shuang Chang,Yang Shao,Jun Guo,Jianming Ying,Lu Si

DOI: https://doi.org/10.1158/2767-9764.25913656.v1

2024-01-01

Abstract:Supplementary Table 1. The univariate and multivariate COX analyses for OS associated DMRs in PMME patients.
Anti-tumor immune response varies among individuals: A gene expression profiling of mouse melanoma

Xiaoyue Yang,Zhiming Ma,Ying Zhang,Jingcheng Wu,Jin Huang,Wenyi Zhao,Fan Mo,Zhiwei Lin,Yingchun Xu,Zhan Zhou,Shuqing Chen

DOI: https://doi.org/10.1016/j.intimp.2020.106211

IF: 5.714

2020-01-01

International Immunopharmacology

Abstract:Melanoma is amongst the most aggressive malignant tumors. The purpose of this study is to detect the tumor microenvironment systematically using multi-omits analyses and to propose strategies for precision medicine. Multiple factors of tumor microenvironment contribute to the drug resistance and immune surveillance failure. Here we analyzed genome mutations and characterized the immune state of tumor microenvironments in mouse melanoma by whole exome sequencing (WES) and RNA sequencing (RNA-Seq) approaches. Somatic mutation analysis revealed 35.1% novel mutations in mouse tumors when compared with B16F10 cell line, provided a basis for multi-site sequencing for accurate neoantigen selection. Mutation cluster, gene expression comparison, and gene ontology (GO) analyses by R packages proved DNA repair damage, inflammation, slower cell division, and metabolic change in tumor microenvironment. Further analyses of T-cell receptor (TCR) sequences, immune signaling pathway activation, tumor infiltrated immune cells and chemokine expression revealed extensive difference of antitumor immune response among individuals. Our study revealed the characteristics of tumor microenvironment with mouse melanoma model, suggested the need of comprehensive genome mutations and personal immune state analyses for cancer precision medicine.
Comprehensive Profiling of MDM2/TP53 Genomic Aberration in Chinese Patients with Diverse Malignancies.

Dongkai Zhou,Weilin Wang,Sheng Yan,Song Ye,Yingsheng Wu,Yuan Ding,Qiang Sun,Xiaohui Qian,Bingqiang Gao,Yong Kong,Qifan Yang,Weiping Ji,Zhihai Zhneg,Xiumin Zhou,Weihua Xu,Mingjin She,Yong Yang,Qiantong Dong,Yaojun Yu,Shiyue Zhang

DOI: https://doi.org/10.1200/jco.2020.38.15_suppl.e13508

IF: 45.3

2020-01-01

Journal of Clinical Oncology

Abstract:e13508 Background: Murine double minute-2 (MDM2) has increasing clinic relevance as preclinical and early clinical evidences have showed that the MDM2 inhibitors are promising alternative treatments for patients with MDM2-amplified (-amp) and TP53-wild-type (-WT) tumors by preventing TP53 protein degradation. However, exploration into genomic landscape of MDM2/TP53 across various solid tumors in Chinese patients is still limited. Methods: Formalin-fixed, paraffin-embedded (FFPE) tumor samples were collected from 10010 Chinese patients with solid tumors and subjected to a clinical-grade next-generation sequencing (NGS)-based 450 gene panel testing carried out by a College of American Pathologists (CAP) accredited and Clinical Laboratory Improvement Amendments (CLIA) certified laboratory. Genomic alterations (GAs) including single base substitutions, short and long insertion/deletions (Indels), copy number variations, gene fusions, and rearrangements were analyzed. Tumor mutational burden (TMB) was measured by a NGS algorithm. Results: Amplification of MDM2 occurred in 3.3% of Chinese patients. MDM2-amp was detected most frequently in soft tissue sarcoma (STS, 11.4 %), melanoma (10.3 %) and osteosarcoma (6.3 %). Notably, MDM2-amp was revealed to be mutually exclusive with TP53-mut in most tumor types other than esophageal carcinoma (93.9 %), head and neck carcinoma (68.4%) and ovarian carcinoma (50 %). Tumors with highest frequencies of MDM2-amp/ TP53-WT were melanoma (100%), osteosarcoma (100%) and urothelial carcinoma (100 %). The most common co-altered genes accompanied with MDM2-amp were FRS2 (84%), CDK4 (38%), EGFR (26%), TP53 (17%) and GLI1 (14%). 82.8% patients who had one or more co-alterations potentially targetable with either FDA-approved or investigational agent. Moreover, TMB of MDM2-amp tumors were significantly lower than that of MDM2-WT and MDM2-mutation (-mut) tumors (median TMB: 3.1 vs. 4.6 vs. 10.8, p < 0.001 respectively). Conclusions: MDM2 amplification was found in 3.3% of 10010 Chinese cancer patients, 83.4% of whom harbored wild-type TP53 that were potentially responsive to MDM2 inhibitors. In addition, 82.8% of the patients with MDM2-amp harbored genomic co-alterations and were potentially therapy targetable. This study provided insights into identifying patients who might potentially benefit from anti-MDM2 therapies.
TABLE 1 from Comparative Epigenetic Profiling Reveals Distinct Features of Mucosal Melanomas Associated with Immune Cell Infiltration and Their Clinical Implications

Jie Dai,Jia Jia,Fanshuang Zhang,Kaihua Liu,Yanfeng Xi,Pei Yuan,Lili Mao,Xue Bai,Xiaoting Wei,Bingning Wang,Jiangtao Li,Yang Xu,Ting Liu,Shuang Chang,Yang Shao,Jun Guo,Jianming Ying,Lu Si

DOI: https://doi.org/10.1158/2767-9764.25913659.v1

2024-01-01

Abstract:Demographic and clinical characteristics of the patients with PMME and NEMM included in the study
Table S3 from Comparative Epigenetic Profiling Reveals Distinct Features of Mucosal Melanomas Associated with Immune Cell Infiltration and Their Clinical Implications

Jie Dai,Jia Jia,Fanshuang Zhang,Kaihua Liu,Yanfeng Xi,Pei Yuan,Lili Mao,Xue Bai,Xiaoting Wei,Bingning Wang,Jiangtao Li,Yang Xu,Ting Liu,Shuang Chang,Yang Shao,Jun Guo,Jianming Ying,Lu Si

DOI: https://doi.org/10.1158/2767-9764.25913650

2024-01-01

Abstract:Supplementary Table 3. The immune-related pathways that were enriched in TERT methylation high group versus TERT methylation low group using GSEA analysis.
Table S1-S3 from Multiregional Sequencing Reveals Genomic Alterations and Clonal Dynamics in Primary Malignant Melanoma of the Esophagus

Jingjing Li,Shi Yan,Zhen Liu,Yong Zhou,Yaqi Pan,WenQin Yuan,Mengfei Liu,Qin Tan,Geng Tian,Bin Dong,Hong Cai,Nan Wu,Yang Ke

DOI: https://doi.org/10.1158/0008-5472.22417647.v1

2023-01-01

Abstract:Table S1: SNV list Table S2: Indel list Table S3: Mutaion frequency of TCGA sample
Figure S2 from Comparative Epigenetic Profiling Reveals Distinct Features of Mucosal Melanomas Associated with Immune Cell Infiltration and Their Clinical Implications

Jie Dai,Jia Jia,Fanshuang Zhang,Kaihua Liu,Yanfeng Xi,Pei Yuan,Lili Mao,Xue Bai,Xiaoting Wei,Bingning Wang,Jiangtao Li,Yang Xu,Ting Liu,Shuang Chang,Yang Shao,Jun Guo,Jianming Ying,Lu Si

DOI: https://doi.org/10.1158/2767-9764.25913665

2024-01-01

Abstract:Supplementary Figure S2. Diagram illustrating the genomic loci of the 7-DMR panel.
Supplementary Table 14 from A Meta-analysis of Somatic Mutations from Next Generation Sequencing of 241 Melanomas: A Road Map for the Study of Genes with Potential Clinical Relevance

Junfeng Xia,Peilin Jia,Katherine E. Hutchinson,Kimberly B. Dahlman,Douglas Johnson,Jeffrey Sosman,William Pao,Zhongming Zhao

DOI: https://doi.org/10.1158/1535-7163.22500162

2023-01-01

Abstract:XLSX - 28K, Supplementary Table S14. Mutations in 12 potential cancer genes in pan-negative melanoma samples.
Table S2 from Comparative Epigenetic Profiling Reveals Distinct Features of Mucosal Melanomas Associated with Immune Cell Infiltration and Their Clinical Implications

Jie Dai,Jia Jia,Fanshuang Zhang,Kaihua Liu,Yanfeng Xi,Pei Yuan,Lili Mao,Xue Bai,Xiaoting Wei,Bingning Wang,Jiangtao Li,Yang Xu,Ting Liu,Shuang Chang,Yang Shao,Jun Guo,Jianming Ying,Lu Si

DOI: https://doi.org/10.1158/2767-9764.25913653

2024-01-01

Abstract:Supplementary Table 2. The immune-related pathways that were enriched in PMME when compared with NEMM using GSEA analysis.
Distinct Genomic Traits Of Acral And Mucosal Melanomas Revealed By Targeted Mutational Profiling

Zhengyun Zou,Qiuxiang Ou,Yu Ren,Qing Lv,Lanqun Qin,Lianjun Zhao,Shu Su,Xue Wu,Hua Bao,Ao Wang,Dongqin Zhu,Xiaonan Wang,Yang W Shao,Baorui Liu

DOI: https://doi.org/10.1111/pcmr.12865

2020-01-01

Pigment Cell & Melanoma Research

Abstract:The incidence of melanoma is rising globally including China. Comparing to Caucasians, the incidence of non-cutaneous melanomas is significantly higher in Chinese. Herein, we performed genomic profiling of 89 Chinese surgically resected primary melanomas, including acral (n = 54), cutaneous (n = 22), and mucosal (n = 13), by hybrid capture-based next-generation sequencing. We show that mucosal melanomas tended to harbor more pathogenic mutations than other types of melanoma, though the biological significance of this finding remains uncertain. Chromosomal arm-level alterations including 6q, 9p, and 10p/q loss were highly recurrent in all subtypes, but mucosal melanoma was significantly associated with increased genomic instability. Importantly, 7p gain significantly correlated with unfavorable clinical outcomes in non-cutaneous melanomas, representing an intriguing prognostic biomarker of those subtypes. Furthermore, focal amplification of 4q12 (KIT, KDR, and PDGFR alpha) and RAD51 deletion were more abundant in mucosal melanoma, while NOTCH2 amplification was enriched in acral melanoma. Additionally, cutaneous melanomas had higher mutation load than acral melanomas, while mucosal melanomas did not differ from other subtypes in mutation burden. Together, our data revealed important features of acral and mucosal melanomas in Chinese including distinctive driver mutation pattern and increased genomic instability. These findings highlight the possibilities of combination therapies in the clinical management of melanoma.
Whole-exome Sequencing Reveals Mutational Profiles of Anorectal and Gynecological Melanoma

Wei Sun,Kunyan Liu,Hongyu Zhou,Fang Zhao,Yan Dong,Yu Xu,Yunyi Kong,Minghe Wang,Xi Cheng,Yong Chen

DOI: https://doi.org/10.1007/s12032-023-02192-6

2023-01-01

Medical Oncology

Abstract:Mucosal melanoma is a rare and highly malignant type of melanoma. Among the sites that mucosal melanoma arises, anorectal and gynecological melanoma has more aggressive behavior and worse prognosis. There was no effective therapy for mucosal melanoma at present. Only a small number of mucosal melanoma patients which harbor mutations in BRAF or KIT benefit from targeted therapy. So it's an urgent need to identify more actionable mutations in mucosal melanoma. To identify more potential therapeutic targets in mucosal melanoma, 48 samples were collected from 44 patients with anorectal or gynecological melanoma and subjected to whole-exome sequencing. The tumor mutation burden was low with a median of 1.75 mutations per Mb. In chromosomal level, 1q, 6p and 8q of mucosal melanoma were significantly amplified while 9p, 10p, 10q, 16p and 16q were significantly deleted. Muc16 was the most frequently mutated oncogene in our samples(25%). The mutation frequency of KIT(20%) was comparable to the "triple-wild" genes-NRAS(20%), NF1(20%), and BRAF(11%). KMT2D mutation was found in 18.18% patients, which is previously unidentified. MAPK signaling pathway and lysine degradation were the most frequently mutated pathways. Moreover, patients with TP53 mutations tend to have worse clinical outcome (median survival time 19 vs. 50 months, log-rank P = 0.006). 2000 ore mutated genes involved in MAPK signaling pathway were identified, which expand the patients potentially benefit from ample MAPK inhibitors. KMT2D could be a potential therapeutic target. Moreover, TP53 could be a potential prognosis marker for mucosal melanoma.
Comprehensive Genomic Profiling Reveals Distinct Patterns of Driver Mutations and Chromosomal Alterations in Acral and Mucosal Melanomas.

Zhengyun Zou,Qiuxiang Ou,Yu Ren,Qing Lv,Lanqun Qin,Lianjun Zhao,Shu Su,Xue Wu,Hua Bao,Ao Wang,Dongqin Zhu,Xiaonan Wang,Yang Shao,Baorui Liu

DOI: https://doi.org/10.1200/jco.2019.37.15_suppl.9576

IF: 45.3

2019-01-01

Journal of Clinical Oncology

Abstract:9576 Background: The incidence of melanoma subtypes differs significantly among ethnicities. Ultraviolet (UV) radiation-driven melanomas are common in Caucasians, while non-cutaneous melanomas including acral and mucosal melanomas are more frequent in Asians. It will be of great interest and clinical relevance to decipher the molecular pathogenesis of different melanoma subtypes. Methods: We retrospectively studied a cohort of 89 Chinese melanoma patients who underwent surgical resection of their primary tumors followed by chemotherapy. Genomic profiling of primary melanomas was performed using next generation sequencing by targeting 422 cancer-relevant genes. The Kaplan-Meier method and logrank test were used for survival analysis, and a cox model was used for multivariate survival analysis. Results: Acral melanomas (54/89, 60%) were the most common subtype of this cohort, while cutaneous and mucosal subtypes accounted for 25% and 15%, respectively. Mutation profiling revealed that BRAF was most frequently mutated in cutaneous melanomas, but aberrant BRAF, RAS, KIT, and NF1 were almost evenly represented in acral and mucosal melanomas; of note, mucosal melanomas had a propensity for concurrent driver mutations. Chromosomal alterations were detected across all subtypes, and chr7p amplification significantly correlated with poor prognosis while independently of melanoma subtypes. Furthermore, acral and mucosal melanomas demonstrated higher rates of focal copy number variations (CNVs) than cutaneous melanomas. The amplification of CDK4/CCND1 and NOTCH2 was observed predominantly in acral melanomas , and RAD51 loss was significantly enriched in mucosal melanomas correlating with poor survival. In addition, the tumor mutation burden (TMB) was significantly lower in acral or mucosal melanomas than in cutaneous melanomas. Conclusions: Our findings revealed distinct patterns of driver mutations and chromosomal alterations in acral and mucosal melanomas in contrast to cutaneous melanoma, and highlighted the association of chromosome 7p amplification and RAD51 deletion with unfavourable survival in melanoma patients treated with standard chemotherapy.
Next-generation Sequencing in Advanced Chinese Melanoma Reveals Therapeutic Targets and Prognostic Biomarkers for Immunotherapy.

Fuxue Huang,Jingjing Li,Xizhi Wen,Baoyan Zhu,Wei Liu,Jiuhong Wang,Hang Jiang,Ya Ding,Dandan Li,Xiaoshi Zhang

DOI: https://doi.org/10.1038/s41598-022-13391-y

IF: 4.6

2022-01-01

Scientific Reports

Abstract:Limited studies have interrogated the genomic landscape of Chinese melanoma in which acral and mucosal melanoma are the mainstay. In this study, we carried out a retrospective analysis on 81 Chinese melanoma patients (15 acral, 25 mucosal and 41 cutaneous melanoma). With the identification of 1114 mutations spanning 248 genes, we summarized that the mutation spectrum varied significantly by subtypes. Acral melanoma and mucosal melanoma had significantly more CNVs. MYC amplification was one of the most commonly detected CNVs, other frequent CNVs in mucosal melanoma included NBN and KDR, which were associated with the poor survival of melanoma patients. A generally low TMB, with a median of only 5.1 mut/Mb, was observed in three groups including cutaneous melanoma. Additionally, over 50% variants in DNA damage repair pathway were detected in all three subtypes, most of which were HRD related genes. Patients with alterations of HRD related genes had a longer survival time after immunotherapy. This study revealed a molecular profiling of Chinese patients with advanced melanoma, and proposed the high variant rate in DDR pathway as a biomarker of immunotherapy, which might provide therapeutic targets and guidance in making clinical decision for different Chinese melanoma.
Integrative Analysis of Minichromosome Maintenance Proteins and Their Prognostic Significance in Melanoma

Wei Han,Yi-Zhu Wu,Xiao-Yu Zhao,Zhen-Hua Gong,Guo-Liang Shen

DOI: https://doi.org/10.3389/fonc.2021.715173

IF: 4.7

2021-08-19

Frontiers in Oncology

Abstract:Background Minichromosome maintenance ( MCM ) is known for participating in cell cycle progression, as well as DNA replication. While the diverse expression patterns and prognostic values of MCM s in melanoma still remained unclear. Methods In the present study, the transcriptional and clinical profiles of MCM s were explored in patients with melanoma from multiple databases, including GEO, TCGA, ONCOMINE, GEPIA, UALCAN, cBioPortal, and TIMER databases. Results We found that the elevated expressions of MCM2–6 and MCM10 were significantly expressed in melanoma compared to normal skin. High mRNA levels of MCM4 , MCM5 , and MCM10 were closely related to worse prognosis in patients with melanoma. GSEA showed hallmark pathways were most involved in mTORC1 signaling, G2M checkpoint, E2F targets, and mitotic spindle. Furthermore, we found potential correlations between the MCM expression and the immune cell infiltration, including B cells, CD4+ T cells, CD8+ T cells, neutrophils, macrophages, and dendritic cells. Conclusion Upregulated MCM gene expression in melanoma probably played a crucial part in the development and progression of melanoma. The upregulated MCM4/5/10 expressions could be used as potential prognostic markers to improve the poor outcome and prognostic accuracy in patients with melanoma. Our study might shed light on the selection of prognostic biomarkers as well as the underlying molecular pathogenesis of melanoma.

oncology

Table S1 from Analysis of Mucosal Melanoma Whole-Genome Landscapes Reveals Clinically Relevant Genomic Aberrations

Table S3 from Analysis of Mucosal Melanoma Whole-Genome Landscapes Reveals Clinically Relevant Genomic Aberrations

Table S2 from Analysis of Mucosal Melanoma Whole-Genome Landscapes Reveals Clinically Relevant Genomic Aberrations

Table S6 from Analysis of Mucosal Melanoma Whole-Genome Landscapes Reveals Clinically Relevant Genomic Aberrations

Analysis of Mucosal Melanoma Whole-Genome Landscapes Reveals Clinically Relevant Genomic Aberrations

Single-Cell Characterization of the Immune Microenvironment of Melanoma Brain and Leptomeningeal Metastases.

Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets.

Table S1 from Comparative Epigenetic Profiling Reveals Distinct Features of Mucosal Melanomas Associated with Immune Cell Infiltration and Their Clinical Implications

Anti-tumor immune response varies among individuals: A gene expression profiling of mouse melanoma

Comprehensive Profiling of MDM2/TP53 Genomic Aberration in Chinese Patients with Diverse Malignancies.

TABLE 1 from Comparative Epigenetic Profiling Reveals Distinct Features of Mucosal Melanomas Associated with Immune Cell Infiltration and Their Clinical Implications

Table S3 from Comparative Epigenetic Profiling Reveals Distinct Features of Mucosal Melanomas Associated with Immune Cell Infiltration and Their Clinical Implications

Table S1-S3 from Multiregional Sequencing Reveals Genomic Alterations and Clonal Dynamics in Primary Malignant Melanoma of the Esophagus

Figure S2 from Comparative Epigenetic Profiling Reveals Distinct Features of Mucosal Melanomas Associated with Immune Cell Infiltration and Their Clinical Implications

Supplementary Table 14 from A Meta-analysis of Somatic Mutations from Next Generation Sequencing of 241 Melanomas: A Road Map for the Study of Genes with Potential Clinical Relevance

Table S2 from Comparative Epigenetic Profiling Reveals Distinct Features of Mucosal Melanomas Associated with Immune Cell Infiltration and Their Clinical Implications

Distinct Genomic Traits Of Acral And Mucosal Melanomas Revealed By Targeted Mutational Profiling

Whole-exome Sequencing Reveals Mutational Profiles of Anorectal and Gynecological Melanoma

Comprehensive Genomic Profiling Reveals Distinct Patterns of Driver Mutations and Chromosomal Alterations in Acral and Mucosal Melanomas.

Next-generation Sequencing in Advanced Chinese Melanoma Reveals Therapeutic Targets and Prognostic Biomarkers for Immunotherapy.

Integrative Analysis of Minichromosome Maintenance Proteins and Their Prognostic Significance in Melanoma